Search the Newsreel

MAXIMUS, Inc. Revenue Breakdown – LS:907462

MAXIMUS, Inc. generated 4.63 billion EUR in revenue last year, with its United States Federal Services segment contributing 2.61 billion EUR. The U.S. was the largest regional contributor, accounting for 4.12 billion EUR of the total revenue. This article details the top segments and …

How Maximus’ Higher Dividend Yield and Low Payout Ratio Could Shape MMS Investors’ Income Outlook

Maximus, Inc. recently announced a 10% increase in its annualized dividend, resulting in a 2.29% yield, which surpasses its industry and the S&P 500, while maintaining a low 17% payout ratio. This move, coupled with projected earnings growth for 2026 and sustained revenue guidance, …

MMS|Maximus Inc|Price:61.297|Chg%:+1.627

This article provides a comprehensive stock analysis of Maximus Inc (MMS) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation. The report notes high institutional ownership and a "Buy" rating from multiple analysts with a target price of $105.00. Despite good …

Replimune Group Inc (REPL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Replimune Group Inc (REPL), highlighting its major institutional holders and their proportion of shares. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent activities of top shareholders. Additionally, it lists several …

Optimum Communications, Inc. Revenue Breakdown – NYSE:OPTU

Maximus Inc (MMS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Maximus Inc (MMS), listing major institutional holders like BlackRock, Fidelity, and Vanguard, along with their respective proportions. It also presents a breakdown of shareholder types such as investment advisors and pension funds. Additionally, the report includes institutional …

MMS|Maximus Inc|Price:59.190|Chg%:+0.740

Imunon, Inc. (IMNN) stock price, news, quote and history

Imunon, Inc. (IMNN) stock experienced a decline, trading at $1.5000 with a -0.66% change after hours on July 24, 2026. The clinical-stage biotechnology company focuses on developing immunotherapies and vaccines, with lead programs including IMNN-001 for ovarian cancer and IMNN-101 for COVID-19. The article …

Simulations Plus Sets Shareholder Vote on Cash Merger with Altaris Affiliate

Simulations Plus has scheduled a virtual special shareholder meeting for August 27, 2026, to vote on a proposed cash merger with SP Evolution BidCo II, LLC, an affiliate of Altaris. The deal, which offers shareholders $18.50 per share, representing a 26% premium, is unanimously …

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

IMUNON, Inc. (Nasdaq: IMNN) announced it will present new data on its DNA-based IL-12 immunotherapy, IMNN-001, for advanced ovarian cancer at the inaugural AACR Conference on Drug Discovery and Development. The presentation will highlight findings from the Phase 2 OVATION-2 study, demonstrating IMNN-001's safety, …

Maximus (MMS) Could Be a Great Choice

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. While cash flow can …

Replimune stock trades lower after cash burn and clinical updates shape outlook

Replimune Group Inc. (NASDAQ: REPL), an immuno-oncology company, is seeing its stock trade lower following financial results that show increasing operating losses despite a strong cash reserve and progressing clinical trials. The company's lead product candidate, RP1, is an oncolytic immunotherapy undergoing multiple clinical …

IMUNON presents promising Phase 2 data for IMNN-001 immunotherapy in advanced ovarian cancer at AACR D3 conference.

IMUNON, Inc. presented positive Phase 2 clinical trial data for its DNA-based immunotherapy, IMNN-001, at the AACR D3 conference. The data indicates that IMNN-001 can significantly improve overall survival in patients with advanced ovarian cancer by locally delivering interleukin-12 to tumors, enhancing immune response …

Ovarian cancer trial links IMUNON's IMNN-001 to 14.7 more months

IMUNON (Nasdaq: IMNN) announced new translational and clinical data on its DNA-based IL-12 immunotherapy, IMNN-001, for advanced ovarian cancer, to be presented at the AACR D3 conference. The data highlights a numerical median overall survival increase of 14.7 months for IMNN-001 plus chemotherapy compared …

What Tesla’s Q2 Earnings Reveal About the Real Price of Scaling Optimus

Price to earnings forward of Imunon, Inc. – LSE:0HUZ

This article provides financial information for Imunon, Inc. (LSE:0HUZ), specifically focusing on its price-to-earnings forward metric. The content is primarily a data point embedded within a larger financial data platform, TradingView, highlighting the value and change of this financial indicator. The article doesn't offer …

IMUNON's IL-12 Therapy Breaks Ovarian Cancer Safety Barrier

Imunon's IL-12 gene therapy (IMNN-001) has shown promising early safety and efficacy signals in Phase II trials for newly diagnosed advanced ovarian cancer. Preliminary data indicate lower rates of residual disease and higher circulating tumor DNA clearance in patients receiving IMNN-001 compared to control, …

Replimune Group Reaches Analyst Target Price

In recent trading, shares of Replimune Group Inc (Symbol: REPL) have crossed above the average analyst 12-month target price of $10.67, changing hands for $11.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade …

Insider Sell: Susan Eylward Sells 2,150 Shares of Imunon Inc (IMNN)

Susan Eylward, General Counsel and Corporate Secretary at Imunon Inc's subsidiary, sold 2,150 shares of Imunon Inc (IMNN) on July 20, 2026. After this transaction, Eylward now holds 2,896 shares. This sale contributes to a total of three insider sells and no insider buys …

Imunon (IMNN) counsel granted, then sells 2,150 shares of Common Stock

Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, reported two Common Stock transactions. She first received 2,150 shares at $1.83 each as part of her base salary on July 17, 2026. Three days later, on July 20, 2026, Eylward sold all 2,150 of …

Imunon general counsel Susan Eylward sells $3,830 in stock

Imunon's general counsel, Susan Eylward, recently sold 2,150 shares worth $3,830 after acquiring the same number of shares as part of her salary compensation. These transactions occurred while the stock trades near its 52-week low, though InvestingPro analysis suggests it is undervalued with high …

Replimune stock gains after updated RP1 data and cash runway outlook

Replimune Group Inc. (REPL) stock is reacting to updated clinical data for its oncolytic immunotherapy RP1 and a strengthened cash position. The company reported $357 million in cash and short-term investments as of March 31, 2024, which management expects will fund operations into 2028. …

Imunon, Inc. (IMNN) chair receives 4,603-share stock salary grant

Imunon, Inc.'s executive chairman, Michael H. Tardugno, received a grant of 4,603 shares of common stock on July 17, 2026, as compensation in lieu of a cash base salary. The shares were valued at $1.83 each. Following this transaction, Tardugno directly holds 68,999 shares …

Imunon (IMNN) grants stock in lieu of salary to CMO

Imunon, Inc. (IMNN) granted 3,082 shares of common stock to Chief Medical Officer Douglas Vincent Faller on July 17, 2026, as part of his compensation package. These shares, valued at $1.83 each, were provided in lieu of a portion of his base salary. Following …

Imunon (IMNN) CEO awarded stock instead of cash salary portion

Imunon, Inc.'s President and CEO, Stacy Lindborg, received a grant of 4,907 shares of common stock on July 17, 2026, valued at $1.83 per share. This stock award was issued in lieu of a portion of her cash base salary. Following this transaction, Lindborg …

IMUNON Phase 2 Data Show IMNN-001 Improves MRD Outcomes In Ovarian Cancer

(RTTNews) - IMUNON, Inc. (IMNN), a clinical-stage biotechnology company, announced Tuesday positive preliminary data from the ongoing Phase 2 minimal residual disease (MRD) trial evaluating IMNN-001 in combination with standard-of-care chemotherapy and bevacizumab in women with newly diagnosed advanced ovarian cancer. IMNN-001 is an …

IMUNON reports preliminary Phase 2 data for ovarian cancer drug

IMUNON, Inc. (NASDAQ:IMNN) has reported preliminary Phase 2 data for its investigational drug IMNN-001 in advanced ovarian cancer staged for primary debulking surgery. The data indicates a lower minimal residual disease-positive rate and higher circulating tumor DNA clearance in patients treated with IMNN-001 compared …

IMUNON's IMNN-001 shows promising Phase 2 ovarian cancer data with improved disease clearance and safety.

IMUNON, Inc. announced positive preliminary Phase 2 data for its DNA-mediated immunotherapy IMNN-001 in advanced ovarian cancer. The study showed lower minimal residual disease rates and higher circulating tumor DNA clearance, along with a favorable safety profile. These results support IMNN-001's potential to improve …

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

IMUNON announced positive preliminary Phase 2 clinical data for its IMNN-001 immunotherapy in newly diagnosed advanced ovarian cancer. The study, conducted in partnership with Break Through Cancer, showed a lower minimal residual disease (MRD)-positive rate, higher circulating tumor DNA (ctDNA) clearance, and a highly …

Precision Trading with Simulations Plus Inc. (SLP) Risk Zones

Simulations Plus Inc. (SLP) is showing a neutral sentiment across all horizons, leading to a wait-and-see approach. AI models suggest several trading strategies, including a short setup with a high risk-reward ratio, targeting a 16.5% downside. The article details entry, target, and stop-loss zones …

Simulations Plus (NASDAQ:SLP) Share Price Crosses Above 200-Day Moving Average - Time to Sell?

Simulations Plus (NASDAQ: SLP) saw its share price move above its 200-day moving average, reaching $18.25 despite cautious analyst sentiment and recent downgrades. The company reported strong quarterly earnings, beating expectations with an EPS of $0.30 and revenue of $21.89 million. While a director …

Simulations Plus (SLP) to go private in $375M all‑cash sale to Altaris

Simulations Plus (SLP) is set to go private through a $375 million all-cash sale to Altaris, with shareholders receiving $18.50 per share. This represents a 26% premium over the 60-day volume-weighted average price prior to June 15, 2026. The acquisition is expected to close …

ETFs Investing in Replimune Group, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Replimune Group, Inc. (A2JQN1) stocks, offering investors diversified exposure to the company. The ETFs are sorted by their market value of Replimune holdings and include details such as issuer, management style, expense ratio, AUM, …

Yimutian (NasdaqCM:YMT) Stock Price

Yimutian Inc. (NasdaqCM:YMT) has a market cap of US$2.5 million and is described as low risk and slightly overvalued. The company recently announced the full deployment of its WolaiCai AI Agent across all platforms, which is generating significant daily revenue and has increased potato …

Simulations Plus | 144: Notice of proposed sale of securities pursuant to Rule 144

This document is a formal notification regarding the proposed sale of securities by Simulations Plus, carried out under Rule 144 of the Securities Act of 1933. Rule 144 allows for the public resale of restricted and control securities if certain conditions are met. The …

Lobbying Update: $80,000 of MAXIMUS INC. lobbying was just disclosed

A recent Lobbying Disclosure Act filing revealed that MAXIMUS INC. spent $80,000 on lobbying during Q2 2026, primarily on "Workforce issues." The article also details recent insider trading activity for MMS, including purchases by the CEO and CFO, and sales by another executive. Additionally, …